Life sciences company Seer's Q3 net loss narrows

Reuters11-07

Life sciences company Seer's Q3 net loss narrows

Overview

Seer Q3 2025 revenue rose 2% yr/yr to $4.1 mln, driven by product and service sales
Net loss for Q3 2025 was $18.2 mln, an improvement from $21.3 mln last year
Company saw robust demand for Proteograph ONE, increasing instrument shipments

Outlook

Seer expects full-year 2025 revenue between $17 mln and $18 mln

Result Drivers

PROTEOGRAPH DEMAND - Robust demand for Proteograph ONE workflow drove increased instrument shipments
PUBLICATION RECORD - Record number of third-party publications validating Proteograph technology
PRODUCT SALES - Higher product sales contributed to revenue growth

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue		$4.12 mln
Q3 EPS		-$0.32
Q3 Net Income		-$18.23 mln
Q3 Gross Margin		51.00%
Q3 Gross Profit		$2.11 mln
Q3 Operating Expenses		$21.46 mln

Analyst Coverage

The one available analyst rating on the shares is "buy"
The average consensus recommendation for the office equipment peer group is "buy"

Press Release: ID:nGNX6McLPS

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581116046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 06:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581116046","market":"fut","top_or_hot":-1,"title":"Life sciences company Seer's Q3 net loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Life sciences company Seer's Q3 net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Seer Q3 2025 revenue rose 2% yr/yr to $4.1 mln, driven by product and service sales</p></li><li><p>Net loss for Q3 2025 was $18.2 mln, an improvement from $21.3 mln last year</p></li><li><p>Company saw robust demand for Proteograph ONE, increasing instrument shipments</p></li></ul><p><span>Outlook</span></p><ul><li><p>Seer expects full-year 2025 revenue between $17 mln and $18 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PROTEOGRAPH DEMAND - Robust demand for Proteograph ONE workflow drove increased instrument shipments</p></li><li><p>PUBLICATION RECORD - Record number of third-party publications validating Proteograph technology</p></li><li><p>PRODUCT SALES - Higher product sales contributed to revenue growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$4.12 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.32</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.23 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Margin</p></td><td></td><td><p>51.00%</p></td><td></td></tr><tr><td><p>Q3 Gross Profit</p></td><td></td><td><p>$2.11 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$21.46 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the office equipment peer group is \"buy\"</p></li></ul><p>Press Release: <span>ID:nGNX6McLPS</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Life sciences company Seer's Q3 net loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLife sciences company Seer's Q3 net loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 06:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Life sciences company Seer's Q3 net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Seer Q3 2025 revenue rose 2% yr/yr to $4.1 mln, driven by product and service sales</p></li><li><p>Net loss for Q3 2025 was $18.2 mln, an improvement from $21.3 mln last year</p></li><li><p>Company saw robust demand for Proteograph ONE, increasing instrument shipments</p></li></ul><p><span>Outlook</span></p><ul><li><p>Seer expects full-year 2025 revenue between $17 mln and $18 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PROTEOGRAPH DEMAND - Robust demand for Proteograph ONE workflow drove increased instrument shipments</p></li><li><p>PUBLICATION RECORD - Record number of third-party publications validating Proteograph technology</p></li><li><p>PRODUCT SALES - Higher product sales contributed to revenue growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$4.12 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.32</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.23 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Margin</p></td><td></td><td><p>51.00%</p></td><td></td></tr><tr><td><p>Q3 Gross Profit</p></td><td></td><td><p>$2.11 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$21.46 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the office equipment peer group is \"buy\"</p></li></ul><p>Press Release: <span>ID:nGNX6McLPS</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SEER","symbol_name":"Seer, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1KK:1","article_id":"2581116046","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581116046","pubTimestamp":1762466797,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Life sciences company Seer's Q3 net loss narrowsOverviewSeer Q3 2025 revenue rose 2% yr/yr to $4.1 mln, driven by product and service salesNet loss for Q3 2025 was $18.2 mln, an improvement from $21.3","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SEER":"Seer, Inc.","BK4121":"生命科学工具和服务"},"translate_title":"生命科学公司Seer第三季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SEER":0.9},"content_text":"Life sciences company Seer's Q3 net loss narrowsOverviewSeer Q3 2025 revenue rose 2% yr/yr to $4.1 mln, driven by product and service salesNet loss for Q3 2025 was $18.2 mln, an improvement from $21.3 mln last yearCompany saw robust demand for Proteograph ONE, increasing instrument shipmentsOutlookSeer expects full-year 2025 revenue between $17 mln and $18 mlnResult DriversPROTEOGRAPH DEMAND - Robust demand for Proteograph ONE workflow drove increased instrument shipmentsPUBLICATION RECORD - Record number of third-party publications validating Proteograph technologyPRODUCT SALES - Higher product sales contributed to revenue growthKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Revenue$4.12 mlnQ3 EPS-$0.32Q3 Net Income-$18.23 mlnQ3 Gross Margin51.00%Q3 Gross Profit$2.11 mlnQ3 Operating Expenses$21.46 mlnAnalyst CoverageThe one available analyst rating on the shares is \"buy\"The average consensus recommendation for the office equipment peer group is \"buy\"Press Release: ID:nGNX6McLPSFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581116046","isCrawlerRequest":true}